Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 2 |
2011 | 2 |
2012 | 1 |
2013 | 2 |
2014 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Cancer Immunol Immunother. 2013 Dec;62(12):1841-9. doi: 10.1007/s00262-013-1493-8. Epub 2013 Oct 26.
Cancer Immunol Immunother. 2013.
PMID: 24162108
Free PMC article.
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM Jr, Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Bléry M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS.
Benson DM Jr, et al. Among authors: bakan ce.
Blood. 2011 Dec 8;118(24):6387-91. doi: 10.1182/blood-2011-06-360255. Epub 2011 Oct 26.
Blood. 2011.
PMID: 22031859
Free PMC article.
Item in Clipboard
A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells.
Lin L, Benson DM Jr, DeAngelis S, Bakan CE, Li PK, Li C, Lin J.
Lin L, et al. Among authors: bakan ce.
Int J Cancer. 2012 Mar 15;130(6):1459-69. doi: 10.1002/ijc.26152. Epub 2011 Aug 26.
Int J Cancer. 2012.
PMID: 21520044
Free PMC article.
Item in Clipboard
Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma.
Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan CE, Smith MK, Elder P, Krugh D, O'Donnell L, Devine SM.
Benson DM Jr, et al. Among authors: bakan ce.
Leuk Lymphoma. 2010 Feb;51(2):243-51. doi: 10.3109/10428190903480728.
Leuk Lymphoma. 2010.
PMID: 20038230
Free PMC article.
Item in Clipboard
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.
Benson DM Jr, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, Greenfield CN, Porcu P, Devine SM, Rotem-Yehudar R, Lozanski G, Byrd JC, Caligiuri MA.
Benson DM Jr, et al. Among authors: bakan ce.
Blood. 2010 Sep 30;116(13):2286-94. doi: 10.1182/blood-2010-02-271874. Epub 2010 May 11.
Blood. 2010.
PMID: 20460501
Free PMC article.
Item in Clipboard
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA; Alliance for Clinical Trials in Oncology.
Kolitz JE, et al. Among authors: bakan ce.
Cancer. 2014 Apr 1;120(7):1010-7. doi: 10.1002/cncr.28516. Epub 2013 Dec 31.
Cancer. 2014.
PMID: 24382782
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite